ERYtech Pharma has been chosen to present the initial results obtained with its preclinical product GR-ARA1 on sickle cell anemia at the 50th annual congress of the American Society of Hematology (ASH), to be held in San Francisco (United States) from 6 to Dec. 9, 2008.
Sickle cell disease is a genetic disease characterized by the presence of sickle red blood cells in patients suffering from hypoxia (about 100,000 cases in Europe and North America).